Generic drug of Coversyl
Therapeutic class: Cardiology and angiology
Active ingredients: Perindopril
laboratory: Actavis Group Ptc Ehf
Box of 30
Treatment of hypertension.
Stable coronary disease
Reduced risk of cardiac events in patients with a history of myocardial infarction and / or revascularization.
Dosage PERINDOPRIL ACTAVIS 8 mg Tablet Box of 30
It is recommended to take Perindopril once a day in the morning before meals.
The dosage should be adjusted individually according to the patient's profile and blood pressure response (see Warnings and Precautions section ).
Perindopril can be used alone or in combination with other classes of antihypertensive drugs.
The recommended starting dose is 4 mg once a day in the morning.
If there is significant stimulation of the renin-angiotensin-aldosterone system (especially in cases of renovascular hypertension, sodium and / or fluid depletion, cardiac decompensation or severe hypertension), too high a fall in blood pressure may occur. opportunity of the first take. An initial dose of 2 mg is recommended in these patients and treatment initiation will be under medical supervision.
After 1 month of treatment, the dosage can be increased to 8 mg per day in one dose.
Symptomatic hypotension may occur after initiation of treatment with Perindopril; especially in patients treated in parallel with diuretics.
Special attention is therefore recommended in these patients because they may have water and / or salt depletion.
If possible, the diuretic should be stopped 2 to 3 days before initiation of treatment with Perindopril (see Warnings and Precautions section ).
In hypertensive patients, for whom the diuretic can not be interrupted, treatment with perindopril should be initiated with a 2 mg dose. Renal function and serum potassium should be monitored. The dosage of perindopril will then be adjusted according to the blood pressure response. If necessary, treatment with diuretic will be reintroduced.
The treatment of elderly patients should be initiated at a dose of 2 mg which can be gradually increased to 4 mg after one month of treatment and up to 8 mg if necessary, depending on the state of renal function (see table below). ).
Stable coronary disease:
Perindopril will be administered at a dose of 4 mg once daily, then after 2 weeks increased to 8 mg once daily, depending on the state of renal function and provided that the 4 mg dose is well tolerated. .
Elderly patients will receive 2 mg once daily in the first week, then 4 mg once daily the following week before increasing the dose to 8 mg once daily depending on the state of renal function. (see Table 1: "Dosage Adjustment for Renal Failure").
The dosage will be increased only if the tolerance of the previous dose is good.
Dosage adjustment in case of renal insufficiency:
The dosage in patients with renal impairment should be adjusted according to the clearance of creatinine as indicated in Table 1 below:
Table 1: Dosage Adjustment in Renal Impairment
Creatinine clearance (ml / min)
Cl Cr ≥ 60
4mg / day
30 <Cl Cr <60
2mg / day
15 <Cl Cr <30
2 mg every other day
Hemodialysis patient *, Cl Cr <15
2 mg on the day of dialysis
* The dialysis clearance of perindoprilat is 70 ml / min. Patients on hemodialysis should take the dose after the dialysis session.
Dosage adjustment in case of hepatic insufficiency:
No dose adjustment is necessary in patients with hepatic impairment (see Warnings and Precautions for Use and Pharmacokinetics ).
Use in children
Efficiency and job safety have not been fully established. Therefore, use in children is not recommended.
· Hypersensitivity to perindopril, any of the excipients, or other inhibitors of the conversion enzyme (IEC);
· History of angioedema associated with previous treatment with IEC;
· Hereditary or idiopathic angioedema;
· 2nd and 3rd trimesters of pregnancy (see sections Warnings and precautions for use and Pregnancy and lactation ).
Adverse effects Perindopril Actavis
The following adverse reactions have been observed during treatment with perindopril and are classified in the following order of frequency: very common (> 1/10); frequent (≥1 / 100 - <1/10); infrequent (≥1 / 1000 - <1/100); rare (≥1 / 10000 - <1/1000); very rare (<1/10000), unknown (can not be estimated from available data)
Blood and lymphatic system disorders
Cases of decreased hemoglobin and hematocrit, thrombocytopenia, leukopenia / neutropenia and agranulocytosis or pancytopenia have been very rarely described. In patients with congenital glucose-6-phosphate dehydrogenase deficiency, very rare cases of haemolytic anemia have been reported (see Warnings and Precautions ).
Uncommon: Mood or sleep disorders.
Nervous system disorders:
Frequent: Headache, dizziness, vertigo, paresthesia.
Very rare: Mental confusion.
Frequent: Visual disturbances
Affections of the ear and labyrinth
Frequent: hypotension and effects related to hypotension.
Very rare: Rhythmic disorders, angina, myocardial infarction and stroke, which may be secondary to excessive hypotension in high-risk patients (see Warnings and Precautions section ).
Respiratory, thoracic and mediastinal disorders
Common: Cough, dyspnea
Very rare: Eosinophilic pneumonia, rhinitis
Frequent: nausea, vomiting, abdominal pain, dysgeusia, dyspepsia, diarrhea, constipation.
Rare: Dry mouth
Very rare: Pancreatitis
Very rare: Cytolytic or cholestatic hepatitis (see Warnings and precautions for use ).
Skin and subcutaneous tissue disorders
Common: rash, pruritus
Uncommon: Angioedema of the face, extremities, lips, mucous membranes, tongue, glottis and / or larynx, urticaria (see Warnings and Precautions for Use section )
Very rare: Erythema multiforme
Musculoskeletal and systemic disorders
Frequent: Muscle cramps
Renal and urinary disorders
Rare: Renal insufficiency
Very rare: Acute renal failure
Disorders of reproductive organs and breast
Investigations (biological examinations)
Increases in uremia and serum creatinine and reversible hyperkalaemia at discontinuation may occur, particularly in the presence of renal failure, severe heart failure, or renovascular hypertension. Elevations of liver enzymes and bilirubinemia have been observed rarely.
Only serious adverse events were recorded during the randomized phase of the EUROPA study. Some patients experienced serious adverse events: 16 (0.3%) of the 6122 perindopril group and 12 (0.2%) of the 6107 placebo group. In the perindopril group, hypotension occurred in 6 patients, angioedema in 3 and cardiac arrest in 1. Patients discontinued due to cough, hypotension, or other Intolerance was higher in the perindopril group than in the placebo group (6.0% [n = 366] and 2.1%, respectively [n = 129]).